Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is withdrawing approval of one new drug application (NDA) and four abbreviated new drug applications (ANDAs). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
May 14, 2003.Start Further Info
FOR FURTHER INFORMATION CONTACT:
David T. Read, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.End Further Info End Preamble Start Supplemental Information
The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their requests, waived their opportunity for a hearing.
|NDA 17-968||Depo-Testadiol (testosterone cypionate and estradiol cypionate) Injection, 50 milligrams/milliliter (mg/mL) and 2 mg/mL.||Pharmacia & Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001-0199.|
|ANDA 85-603||Testosterone Cypionate-Estradiol Cypionate Injection.||Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043-4706.|
|ANDA 85-860||Testosterone Enanthate and Estradiol Valerate Injection, 180 mg/mL and 8 mg/mL.||Do.|
|ANDA 85-865||Testosterone Enanthate and Estradiol Valerate Injection, 90 mg/mL and 4 mg/mL.||Do.|
|ANDA 86-423||Ditate-DS (testosterone enanthate and estradiol valerate) Injection, 180 mg/mL and 8 mg/mL.||Savage Laboratories, 60 Baylis Rd., Melville, NY 11747.|
The applications listed in the table in this document, all estrogen-androgen combination products, were submitted following a finding by the FDA published in the Federal Register of September 29, 1976 (41 FR 43112). Elsewhere in today's issue of the Federal Register, FDA is initiating a proceeding in which it proposes to amend the 1976 notice. That proceeding will determine if there is substantial evidence of effectiveness of the estrogen-androgen combination products specifically named in the notice proposing to amend the 1976 notice, as well as of any products that are identical, related, or similar (including but not limited to the five products listed in this notice). The agency, therefore, is deferring until the outcome of that proceeding the determination, under § 314.161 (21 CFR 314.161), of whether the five products listed in this notice were withdrawn for reasons of safety or effectiveness.
Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.105), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective May 14, 2003.Start Signature
Dated: April 4, 2003.
Director, Center for Drug Evaluation and Research.
[FR Doc. 03-9064 Filed 4-10-03; 8:45 am]
BILLING CODE 4160-01-S